Antimicrobial peptides: Therapeutic potential for the treatment of Candida infections

Expert Opinion on Investigational Drugs

Volumn 11, Issue 2, 2002, Pages 309-318

  Lupetti, Antonella ^a   Danesi, Romano ^a   van't Wout, Jan W ^a   van Dissel, Jaap T ^a   Senesi, Sonia ^a   Nibbering, Peter H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal agents; Antimicrobial peptide; Defensin; Histatin; Lactoferrin; Protegrin

Indexed keywords

ALPHA DEFENSIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; BETA DEFENSIN; COPPER; DRUG ANALOG; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; HELIOMYCIN; HISTATIN; IB 367; LACTOFERRIN; LYSOZYME; POLYENE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN; PYRROLE DERIVATIVE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; ZINC; ANTIINFECTIVE AGENT; DEFENSIN; DRUG DERIVATIVE; HISTIDINE RICH PROTEINS; HISTIDINE-RICH PROTEINS; PROTEIN;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDIASIS; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; FUNGAL STRAIN; HUMAN; IMMUNE DEFICIENCY; IMMUNOREGULATION; INFECTION RISK; METAL BINDING; MOUSE; MYCOSIS; NONHUMAN; SIDE EFFECT; CANDIDA ALBICANS; DRUG EFFECT; REVIEW;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DEFENSINS; HUMANS; LACTOFERRIN; PROTEINS;

EID: 0036166413     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.2.309     Document Type: Article

References (83)

1. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital
2. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program
3. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada
4. Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients
5. Non-albicans oral candidosis in HIV-positive patients
6. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole
7. Fungal colonization of haematological patients receiving cytotoxic chemotherapy: Emergence of azole-resistant Saccharomyces cerevisiae
8. Phospholipid and sterol analyses of plasma membranes of azole-resistant Candida albicans strains
9. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR
10. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis
11. Transcriptional analyses of antifungal drug resistance in Candida albicans
12. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans
13. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors
14. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity
15. Amino acid substitutions in the cytochrome P450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents
16. Y132H substitution in Candida albicans sterol 14α-demethylase confers fluconazole resistance by preventing binding to haem
17. The G464S amino acid substitution in Candida albicans sterol 14α-demethylase causes fluconazole resistance in the clinic through reduced affinity
18. The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity
19. 5,6-desaturation
20. Evolution of drug resistance in experimental populations of Candida albicans
21. 19F nuclear magnetic resonance study of fluoropyrimidine metabolism in strains of Candida glabrata with specific defects in pyrimidine metabolism
22. β-Defensins: Linking innate and adaptive immunity through dendritic and T-cell CCR6
23. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium
24. Toll-like receptor-mediated NF-kB activation: A phylogenetically conserved paradigm in innate immunity
25. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria
26. Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death
27. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion
28. Candidacidal activities of human lactoferrin peptides derived from the N terminus
29. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli
30. Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans
31. Candida albicans mutants deficient in respiration are resistant to the small cationic salivary antimicrobial peptide histatin 5
32. Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing of Candida albicans
33. Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways
34. Internal thiols and reactive oxygen species in the candidacidal activity exerted by a N-terminal peptide of human lactoferrin
35. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine
36. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides
37. A PhoP-regulated outer membrane protease of Salmonella enterica serovar Typhimurium promotes resistance to alpha-helical antimicrobial peptides
38. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa
39. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family
40. Antimicrobial peptides in mammalian and insect host defence
41. The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations
42. A peptide antibiotic from human skin
43. Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic
44. Discovery of new human β-defensins using a genomics-based approach
45. Large-scale synthesis and functional elements for the antimicrobial activity of defensins
46. Identification of constituents of human neutrophil azurophil granules that mediate fungistasis against Histoplasma capsulatum
47. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation
48. Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion
49. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells
50. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells
51. Activity of protegrins against yeast-phase Candida albicans
52. Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations
53. Characterization of low-molecular-weight peptides in human parotid saliva
54. Regulation of Candida albicans growth and adhesion by saliva
55. Evaluation of the levels of oral Candida in patients with Sjögren's syndrome
56. Longitudinal study of parotid saliva in HIV-1 infection
57. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides
58. Histatin 3-mediated killing of Candida albicans: Effect of extracellular salt concentration on binding and internalization
59. Antifungal activity of histatin-5 against non-albicans Candida species
60. Salivary histatin 5: Dependence of sequence, chain length and helical conformation for candidacidal activity
61. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase
62. Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease
63. Plasma lactoferrin levels are decreased in end-stage AIDS patients
64. Surface expression of lactoferrin by resting neutrophils
65. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA
66. Activated human γδ T-lymphocytes express functional lactoferrin receptors
67. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier
68. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: Involvement of reactive oxygen species
69. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide
70. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex
71. Regulation of epidermal Langerhans cell migration by lactoferrin
72. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells
73. A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils
74. Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor
75. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid
76. Complete response to severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme
77. Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds
78. Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals
79. Synergistic effects of low doses of histatin 5 and its analogues on amphotericin B antimycotic activity
80. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections
81. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis
82. Human β-defensin-2 is a salt-sensitive peptide antibiotic expressed in human lung
83. Engineered salt-insensitive alpha-defensins with end-to-end circularized structures